Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tax Reform, Device Tax Get More Attention On The Hill

This article was originally published in The Gray Sheet

Executive Summary

Comprehensive tax reform is a top priority of House Republicans this year, Ways and Means Chairman Dave Camp, R-Mich., said last week, providing a potential vehicle for device tax repeal. And the device tax received attention at a Democratic-controlled Senate Budget Hearing last week.

You may also be interested in...



R&D Tax Credit Set For Administrative Expansion, Despite Lapse In Congress

A proposal from the Internal Revenue Service set to be finalized this year would expand the research and experimentation tax credit by making prototypes that are sold eligible for the credit. Meanwhile, the tax credit actually expired on Dec. 31, but lawmakers are working to reauthorize it retroactively.

Comprehensive Tax Reform Touted To Industry By Republican Lawmakers

Republican leaders speaking at the Medical Device Manufacturers Association meeting this month say they are confident that broad-based tax reform can be achieved this year, and that it will be a boon to the device industry.

Sequestration Takes Hold: Full FDA Impact Remains To Be Seen

FDA does not plan to furlough employees as a result of the across-the-board cuts to federal agencies that took effect March 1, but the shortfall will limit some “activities that have already been specifically designated and paid for with user fees.” The administration also took a step to convince Congress to give FDA full access to its user fees.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032776

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel